BiotechTube

LTI-03 + Placebo

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Pulmonary Fibrosis (IPF)

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Trial Timeline

Feb 2, 2026 → Dec 31, 2027

NCT ID
NCT06968845

About LTI-03 + Placebo

LTI-03 + Placebo is a phase 2 stage product being developed by Rein Therapeutics for Idiopathic Pulmonary Fibrosis (IPF). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06968845. Target conditions include Idiopathic Pulmonary Fibrosis (IPF).

What happened to similar drugs?

20 of 20 similar drugs in Idiopathic Pulmonary Fibrosis (IPF) were approved

Approved (20) Terminated (1) Active (0)
✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved
✅Omalizumab + PlacebosNovartisApproved
✅Nintedanib + PirfenidoneRocheApproved
✅Tocilizumab + NSAIDs + CSs + MTXRocheApproved
✅TocilizumabRocheApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06968845Phase 2Recruiting
NCT05954988Phase 1Completed

Competing Products

20 competing products in Idiopathic Pulmonary Fibrosis (IPF)

See all competitors
ProductCompanyStageHype Score
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
50
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
Zimura + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 2
35
Rituximab + cyclosporineSun PharmaceuticalPhase 3
32
E5501EisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
PerampanelEisaiPre-clinical
26
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
35
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
40